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OBJECTIVE — It is unclear how well homeostasis model assessment of -cell function
(HOMA-) predicts diabetes development beyond its components, especially glucose.
RESEARCH DESIGN AND METHODS — We identiﬁed 12,924 nondiabetic Koreans
whohadfastingplasmaglucoseandinsulinconcentrationsmeasuredin2003andagainin2008.
To minimize the impact of differences in baseline glucose concentration, individuals were di-
vided into three glucose categories: normal fasting glucose (NFG, glucose 5.6 mmol/l), im-
paired fasting glucose (IFG-100) (5.6–6.0 mmol/l), and IFG-110 (6.1–6.9 mmol/l).
RESULTS — Diabetesdevelopedin29%ofindividualsintheIFG-110group,comparedwith
5% in IFG-100 and 0.3% in NFG groups. Within each glucose category, those who progressed
to diabetes had higher baseline glucose concentrations (P  0.04). Baseline HOMA-, however,
was not lower but higher in individuals who developed diabetes in the NFG group (P  0.009)
and similar in the IFG-100 and IFG-110 groups.
CONCLUSIONS — These data question the utility of using HOMA- to predict the devel-
opment of diabetes.
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T
hehomeostasismodelassessmentof
-cell function (HOMA-)i sa ni n -
dexofinsulinsecretoryfunctionde-
rived from fasting plasma glucose and
insulin concentrations (1). It has been
used to predict diabetes development in
nondiabetic individuals in four studies
(2–5), and the conclusion in each in-
stance was that a decrease in insulin se-
cretory function, as estimated by
HOMA-, predicted the development of
diabetes and/or impaired glucose toler-
ance.However,becauseitwasalsoshown
in these studies that baseline glucose con-
centration was higher in individuals who
developed diabetes, it could be argued that
the lower values for HOMA- may only be
reﬂecting the difference in glucose concen-
tration.Thecurrentanalysiswasinitiatedto
see if HOMA- provided a more sensitive
assessment of the likelihood of developing
type2diabetesthandidknowledgeofindi-
vidual fasting plasma glucose and insulin
concentrations.
RESEARCH DESIGN AND
METHODS— The institutional re-
viewboardofKangbukSamsungHospital
approved this study. Through review of
electronic medical records, 12,924 pa-
tients were identiﬁed who had a general
health status evaluation in both 2003 and
2008 at Kangbuk Samsung Hospital lo-
cated in Seoul, Korea. Patients were di-
vided based on their 2003 glucose
concentrationsintothreegroupstoreﬂect
normal glucose category (normal fasting
glucose [NFG], glucose 5.6 mmol/l or
100 mg/dl), 2003 American Diabetes
Association–modiﬁed impaired fasting
glucose (IFG) category (IFG-100, 5.6–
6.0 mmol/l or 100–109 mg/dl), and prior
IFG category (IFG-110, 6.1–6.9 mmol/l
or 110–125 mg/dl). Development of dia-
betes was deﬁned as glucose 7 mmol/l
(126 mg/dl) on laboratory examination
in 2008 or diagnosis of diabetes and/or
initiation of diabetes medications.
Laboratory examinations were col-
lected after at least 12 h of fasting, ana-
lyzed in the same core laboratory, and
available from the electronic medical
records. Glucose was measured using the
hexokinase method (Advia 1650 Auto-
analyzer; Bayer Diagnostics, Leverkusen,
Germany). Insulin was measured with an
immunoradiometric assay (Biosource,
Nivelle,Belgium)withanintra-andinter-
assay coefﬁcient of variation of 2.1–4.5%
and 4.7–12.2%, respectively. HOMA-
and HOMA of insulin resistance (HOMA-
IR) were calculated using the online cal-
culator (6).
All statistical analysis was performed
using SPSS (version 12 for Windows;
SPSS, Chicago, IL). Differences in mea-




RESULTS— Out of the total 12,924
individuals, there were 10,132 (78%) in
the NFG group, 2,546 (20%) in the IFG-
100 group, and 246 (2%) in the IFG-110
group. During the 5-year interval from
2003to2008,234individuals(1.8%)de-
veloped diabetes. Being in the IFG-110
group conferred the greatest risk to de-
velop diabetes, with 29% converting to
diabetes, compared with 5% in the IFG-
100 group and 0.3% in the NFG group.
Table 1 compares baseline features of
those who developed diabetes (diabetic)
compared with those who did not (non-
diabetic) by glucose category. Although
agewasrelativelysimilarbetweenthetwo
subgroups within each glucose category,
patients who developed diabetes were
heavier at baseline and more likely to be
male. They also had higher glucose and
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and this was seen in all three glycemic
categories. HOMA- was also higher in
individuals who developed diabetes.
These differences were attenuated when
adjusted for age, sex, and BMI, especially
in the IFG-110 group; however, the
trends remained similar. In particular,
HOMA- remained signiﬁcantly higher
in individuals who developed diabetes in
the NFG group and were similar in the
IFG-100 and IFG-110 groups.
CONCLUSIONS — In contrast to
other studies, we did not ﬁnd a lower
HOMA- to be associated with the devel-
opment of diabetes when individuals had
relatively similar glucose concentrations.
Indeed, if anything, individuals who de-
veloped diabetes tended to have higher
HOMA-, reﬂecting the inadequacies of
the HOMA- calculation.
In an attempt to understand this fun-
damental disparity between the current
ﬁndings and previous studies, we believe
it useful to begin by examining the basis
of the HOMA- calculation. The HOMA
calculation is derived from a computer-
solved model that assumes certain rela-
tionships between basal plasma glucose
and insulin concentration (1,6). Al-
though values of both fasting plasma
glucose and insulin concentrations are
usedtosolvetheequation,thedegreeof
glycemia is often the major determi-
nant.InTable1,forexample,asglucose
increases, insulin concentrations also
increase, but HOMA- declines. In fact,
for individuals with IFG-110 to have
similar HOMA- as individuals with
NFG, insulin concentrations would
have to be 120 pmol/l or double the
actual insulin concentration.
Whenexaminedinthislight,itiseasy
to see why our results differ from others.
There have been four prospective studies
that have evaluated the role of HOMA-
inpredictingdiabetes(2–5).Theyallcon-
cluded that a lower HOMA- was predic-
tive of future diabetes. In three of the
studies that provided results by diabetes
status, baseline glucose was also higher in
individuals who developed diabetes. In
one of the studies, the baseline glucose
was only different by 0.5 mmol/l, and the
baseline HOMA- was not signiﬁcantly
different. In a multiple logistic regression
analysis, HOMA- also did not predict
the development of diabetes when ad-
justed for age, sex, BMI, and waist-to-hip
ratio (odds ratio 0.93 [95% CI 0.69–
1.26]). However, when they added
HOMA-IR to the model, HOMA- be-
came signiﬁcant (0.34 [0.21–0.55]). The
authors therefore concluded that a higher
HOMA- was protective against the de-
velopment of diabetes and emphasized
theimportanceofadjustingforinsulinre-
sistance (HOMA-IR) when evaluating in-
sulin secretion. While this has biological
basis, it should be noted that HOMA-IR
and insulin concentration were nearly
perfectly correlated (r  0.98); therefore,
adding HOMA-IR to the model merely
adjusts for insulin concentration and iso-
lates the effect of glucose concentration
on diabetes risk.
In conclusion, we conﬁrm that base-
line glucose concentration is strongly as-
sociated with diabetes development, with
29% of individuals meeting the old IFG
criteria (IFG-110) progressing to diabetes
within5years.However,individualswho
were at risk to develop diabetes were not
characterizedbyinsulindeﬁciency,asde-
ﬁnedbyabsoluteinsulinconcentrationor
HOMA-. As pancreatic -cell dysfunc-
tion has been established as a requisite
defect in type 2 diabetes (7), these ﬁnd-
ings likely highlight the inadequacies of
fasting measures as surrogates for pancre-
atic function (8,9).
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